Cargando…
Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
Mortalin, a heat shock family protein enriched in cancer cells, is known to inactivate tumor suppressor protein p53. Abrogation of mortalin-p53 interaction and reactivation of p53 has been shown to trigger growth arrest/apoptosis in cancer cells and hence, suggested to be useful in cancer therapy. I...
Autores principales: | Meidinna, Hazna Noor, Shefrin, Seyad, Sari, Anissa Nofita, Zhang, Huayue, Dhanjal, Jaspreet Kaur, Kaul, Sunil C., Sundar, Durai, Wadhwa, Renu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510692/ https://www.ncbi.nlm.nih.gov/pubmed/36172283 http://dx.doi.org/10.3389/fcell.2022.918970 |
Ejemplares similares
-
Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and Mortaparib(Plus)
por: Kumar, Vipul, et al.
Publicado: (2021) -
Mutant p53(L194F) Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib(Plus), a Multimodal Small Molecule Inhibitor
por: Elwakeel, Ahmed, et al.
Publicado: (2021) -
Comparative computational and experimental analyses of some natural small molecules to restore transcriptional activation function of p53 in cancer cells harbouring wild type and p53(Ser46) mutant
por: Shefrin, Seyad, et al.
Publicado: (2022) -
Identification and Characterization of Mortaparib(Plus)—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms
por: Sari, Anissa Nofita, et al.
Publicado: (2021) -
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
por: Putri, Jayarani F., et al.
Publicado: (2019)